Cassava Sciences | PTIE - Des Atouts





Des Atouts Changement Date
Abbott USD 110.43B 23.72B 2026-03
Amgen USD 92.5B 1.92B 2026-03
Biogen USD 29.48B 43.6M 2026-03
Cara Therapeutics USD 32.07M 6.95M 2025-12
Cassava Sciences USD 108.37M 9.99M 2026-03
Eisai JPY 1.45T 37.11B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Geron USD 534.12M 36.42M 2026-03
J&J USD 200.89B 1.68B 2026-03
Merck USD 128.68B 8.18B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Novavax USD 1.04B 133.35M 2026-03
Pfizer USD 207.62B 542M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12